INTRODUCTION: Gadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI. MATERIALS AND METHODS: Multiparametric MRI was performed in 379 patients: 94 patients received 1 M gadobutrol while 285 randomly received equivalent doses of 0.5 M gadoterate meglumine or gadopentetate dimeglumine. MRI images were retrospectively and blindly assessed for the presence of cancer by comparing them with prostate biopsy findings. RESULTS: The specificity and accuracy were significantly higher with 1 M gadobutrol than 0.5 M of the other contrast agents. There were no significant differences in the sensitivity, or positive and negative predictive values. CONCLUSION: Multiparametric MRI using 1 M gadobutrol may improve the accuracy of prostate cancer detection.
INTRODUCTION: Gadobutrol (Gd-DO3A-butrol) (Gadovist®) is a macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI) formulated at 1.0 mmol Gd/ml. Gadobutrol's higher concentration compared to other contrast agents (0.5 mmol Gd/ml) is associated with higher T1 relaxivity. We examined whether gadobutrol increases the accuracy of prostate cancer detection using dynamic contrast-enhanced MRI. MATERIALS AND METHODS: Multiparametric MRI was performed in 379 patients: 94 patients received 1 M gadobutrol while 285 randomly received equivalent doses of 0.5 M gadoterate meglumine or gadopentetate dimeglumine. MRI images were retrospectively and blindly assessed for the presence of cancer by comparing them with prostate biopsy findings. RESULTS: The specificity and accuracy were significantly higher with 1 M gadobutrol than 0.5 M of the other contrast agents. There were no significant differences in the sensitivity, or positive and negative predictive values. CONCLUSION: Multiparametric MRI using 1 M gadobutrol may improve the accuracy of prostate cancer detection.
Entities:
Keywords:
Contrast media; Gadolinium; Magnetic resonance imaging; Prostatic neoplasms
Authors: Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann Journal: Invest Radiol Date: 2005-11 Impact factor: 6.016
Authors: Hebert Alberto Vargas; Oguz Akin; Amita Shukla-Dave; Jingbo Zhang; Kristen L Zakian; Junting Zheng; Kent Kanao; Debra A Goldman; Chaya S Moskowitz; Victor E Reuter; James A Eastham; Peter T Scardino; Hedvig Hricak Journal: Radiology Date: 2012-09-05 Impact factor: 11.105
Authors: Nimalan Arumainayagam; Hashim U Ahmed; Caroline M Moore; Alex Freeman; Clare Allen; S Aslam Sohaib; Alex Kirkham; Jan van der Meulen; Mark Emberton Journal: Radiology Date: 2013-04-05 Impact factor: 11.105
Authors: Baris Turkbey; Haresh Mani; Vijay Shah; Ardeshir R Rastinehad; Marcelino Bernardo; Thomas Pohida; Yuxi Pang; Dagane Daar; Compton Benjamin; Yolanda L McKinney; Hari Trivedi; Celene Chua; Gennady Bratslavsky; Joanna H Shih; W Marston Linehan; Maria J Merino; Peter L Choyke; Peter A Pinto Journal: J Urol Date: 2011-09-25 Impact factor: 7.450
Authors: Hiram Shaish; Whitney Feltus; Jonathan Steinman; Elizabeth Hecht; Sven Wenske; Firas Ahmed Journal: J Am Coll Radiol Date: 2018-03-02 Impact factor: 5.532
Authors: Yaqi Shen; Frank L Goerner; Christopher Snyder; John N Morelli; Dapeng Hao; Daoyu Hu; Xiaoming Li; Val M Runge Journal: Invest Radiol Date: 2015-05 Impact factor: 6.016